Comparing Stevanato Group (NYSE:STVN) & Qiagen (NYSE:QGEN)

Qiagen (NYSE:QGEN) and Stevanato Group (NYSE:STVN) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership and dividends.

Valuation & Earnings

This table compares Qiagen and Stevanato Group”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09 billion	4.38	$424.88 million	$1.95	22.76
Stevanato Group	$1.34 billion	5.11	$158.21 million	€0.56	40.45

Qiagen has higher revenue and earnings than Stevanato Group. Qiagen is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Qiagen has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.

Institutional and Insider Ownership

70.0% of Qiagen shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 0.7% of Stevanato Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Qiagen and Stevanato Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Qiagen	19.49%	14.47%	8.34%
Stevanato Group	10.99%	10.43%	6.16%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Qiagen and Stevanato Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0	9	4	1	2.43
Stevanato Group	0	3	2	2	2.86

Qiagen presently has a consensus price target of $43.51, suggesting a potential downside of 1.98%. Given Qiagen’s higher probable upside, equities analysts plainly believe Qiagen is more favorable than Stevanato Group.

Summary

Qiagen beats Stevanato Group on 10 of the 15 factors compared between the two stocks.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.